Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q01638
UPID:
ILRL1_HUMAN
Alternative names:
Protein ST2
Alternative UPACC:
Q01638; A8K6B3; B4E0I3; Q53TU7; Q8NEJ3; Q9ULV7; Q9UQ44
Background:
Interleukin-1 receptor-like 1, also known as Protein ST2, is a pivotal receptor for interleukin-33 (IL-33), playing essential roles in both innate and adaptive immunity. It contributes to tissue homeostasis and responses to environmental stresses, engaging in complex signaling pathways that involve MYD88, IRAK1, IRAK4, and TRAF6, leading to the activation of MAPKs. This protein is also implicated in helper T-cell function and has a unique role in mitochondrial rewiring and the generation of itaconate for inflammation resolution.
Therapeutic significance:
Understanding the role of Interleukin-1 receptor-like 1 could open doors to potential therapeutic strategies.